Alectinib cleared in Japan

The Japanese Ministry of Health, Labor and Welfare approves Roche's (RHHBY) alectinib for the treatment of patients with non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase fusion gene-positive (ALK+). The product will be available for sale later this year.

In June 2013, the FDA granted alectinib BTD status for ALK+ NSCLC patients who progress on crizotinib.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs